130 related articles for article (PubMed ID: 33443105)
1. mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment.
Haas MS; Kagey MH; Heath H; Schuerpf F; Rottman JB; Newman W
Mol Cancer Res; 2021 Apr; 19(4):717-725. PubMed ID: 33443105
[TBL] [Abstract][Full Text] [Related]
2. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer.
Wall JA; Klempner SJ; Arend RC
Expert Opin Investig Drugs; 2020 Jul; 29(7):639-644. PubMed ID: 32408777
[TBL] [Abstract][Full Text] [Related]
3. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.
Jarman EJ; Horcas-Lopez M; Waddell SH; MacMaster S; Gournopanos K; Soong DYH; Musialik KI; Tsokkou P; Ng ME; Cambridge WA; Wilson DH; Kagey MH; Newman W; Pollard JW; Boulter L
Liver Int; 2023 Jan; 43(1):208-220. PubMed ID: 35924447
[TBL] [Abstract][Full Text] [Related]
4. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R; Dholakia J; Castro C; Matulonis U; Hamilton E; Jackson CG; LyBarger K; Goodman HM; Duska LR; Mahdi H; ElNaggar AC; Kagey MH; Liu A; Piper D; Barroilhet LM; Bradley W; Sachdev J; Sirard CA; O'Malley DM; Birrer M
Gynecol Oncol; 2023 May; 172():82-91. PubMed ID: 37001446
[TBL] [Abstract][Full Text] [Related]
5. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.
D'Amico L; Mahajan S; Capietto AH; Yang Z; Zamani A; Ricci B; Bumpass DB; Meyer M; Su X; Wang-Gillam A; Weilbaecher K; Stewart SA; DeNardo DG; Faccio R
J Exp Med; 2016 May; 213(5):827-40. PubMed ID: 27045006
[TBL] [Abstract][Full Text] [Related]
6. DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer.
Shi T; Zhang Y; Wang Y; Song X; Wang H; Zhou X; Liang K; Luo Y; Che K; Wang X; Pan Y; Liu F; Yang J; Liu Q; Yu L; Liu B; Wei J
Cancer Immunol Res; 2022 Dec; 10(12):1506-1524. PubMed ID: 36206576
[TBL] [Abstract][Full Text] [Related]
7. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
8. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
Betella I; Turbitt WJ; Szul T; Wu B; Martinez A; Katre A; Wall JA; Norian L; Birrer MJ; Arend R
Gynecol Oncol; 2020 Jun; 157(3):765-774. PubMed ID: 32192732
[TBL] [Abstract][Full Text] [Related]
9. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise DR; Pachynski RK; Denmeade SR; Aggarwal RR; Deng J; Febles VA; Balar AV; Economides MP; Loomis C; Selvaraj S; Haas M; Kagey MH; Newman W; Baum J; Troxel AB; Griglun S; Leis D; Yang N; Aranchiy V; Machado S; Waalkes E; Gargano G; Soamchand N; Puranik A; Chattopadhyay P; Fedal E; Deng FM; Ren Q; Chiriboga L; Melamed J; Sirard CA; Wong KK
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341461
[TBL] [Abstract][Full Text] [Related]
12. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
[TBL] [Abstract][Full Text] [Related]
13. Dickkopf-1: A Promising Target for Cancer Immunotherapy.
Chu HY; Chen Z; Wang L; Zhang ZK; Tan X; Liu S; Zhang BT; Lu A; Yu Y; Zhang G
Front Immunol; 2021; 12():658097. PubMed ID: 34093545
[TBL] [Abstract][Full Text] [Related]
14. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
15. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
[No Abstract] [Full Text] [Related]
18. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
19. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]